Founder & Chief Technology Officer (CTO)
Qiaobing Xu is the scientific founder and Chief Technology Officer of Hopewell Therapeutics. He currently serves as a professor in the Department of Biomedical Engineering at Tufts University.
Dr. Xu joined the Tufts faculty in 2010. His research group has primarily focused on developing novel synthetic biodegradable lipids for nucleic acid delivery, including gene therapy and gene editing with organ and cell selectivity. Dr. Xu received the Charlton Award from Tufts University School of Medicine in 2012 and was named a Pew Scholar for Biomedical Sciences by the Pew Charitable Trust in 2013. He also received the National Science Foundation CAREER Award in 2015 and was elected as a Fellow of the American Institute for Medical and Biological Engineering in the Class of 2020. Dr. Xu has published his research extensively in top scientific journals, and his work has resulted in more than 20 issued or pending patents. This body of scientific research and the corresponding intellectual property served as the basis for Dr. Xu to found Hopewell Therapeutics.
Dr. Xu pursued postdoctoral training under the tutelage of Robert Langer, Sc.D. at MIT, where he initiated his innovative research on lipid nanoparticles. Dr. Xu earned his B.Sc. from Jilin University, China and his Ph.D. in Chemistry from Harvard University in the lab of George Whitesides.